NASDAQ:FATE - Fate Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$16.14 -1.62 (-9.12 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$16.14
Today's Range$16.13 - $17.74
52-Week Range$8.35 - $19.11
Volume763,953 shs
Average Volume752,179 shs
Market Capitalization$1.05 billion
P/E Ratio-13.56
Dividend YieldN/A
Beta2.03
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy comprising adaptive memory NK cells; FT500, an induced pluripotent stem cell (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516, an iPSC-derived non-cleavable CD16 engineered NK cell product candidate to treat hematologic malignancies and solid tumors; and FT596, a chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies. The company's immuno-oncology product candidates also include FT538, an NK cell product candidate for treating multiple myeloma; and FT819, a CAR T-cell product candidate for the treatment of liquid and solid tumors. Its immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and FT301, an immuno-regulatory cell product candidate for various disease indications, including graft-versus-host disease, multiple sclerosis, ulcerative colitis, and others. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

Receive FATE News and Ratings via Email

Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FATE
CUSIPN/A
Phone858-875-1800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.74 million
Book Value$2.48 per share

Profitability

Net Income$-66,600,000.00
Net Margins-1,405.06%

Miscellaneous

Employees104
Market Cap$1.05 billion
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable

Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics Inc (NASDAQ:FATE) posted its quarterly earnings results on Tuesday, March, 5th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.01. Fate Therapeutics had a negative net margin of 1,405.06% and a negative return on equity of 59.04%. View Fate Therapeutics' Earnings History.

When is Fate Therapeutics' next earnings date?

Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Fate Therapeutics.

What price target have analysts set for FATE?

6 equities research analysts have issued 12 month price objectives for Fate Therapeutics' shares. Their forecasts range from $12.00 to $24.00. On average, they expect Fate Therapeutics' share price to reach $19.50 in the next year. This suggests a possible upside of 20.8% from the stock's current price. View Analyst Price Targets for Fate Therapeutics.

What is the consensus analysts' recommendation for Fate Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fate Therapeutics.

What are Wall Street analysts saying about Fate Therapeutics stock?

Here are some recent quotes from research analysts about Fate Therapeutics stock:
  • 1. According to Zacks Investment Research, "Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. " (2/13/2019)
  • 2. HC Wainwright analysts commented, "Our $12 price target is based on a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for ProTmune and FATE-NK100. We use the net present value of our revenue forecast through 2026, apply a 40% probability of success for 2Q18 fully diluted net cash estimate of $0.84/share to arrive at our $12 price target. We value the early stage pipeline and Juno collaboration at $2.32/share. We assume a 25% discount rate for the NPV of the pipeline and a P/S multiple of 4x." (8/7/2018)

Has Fate Therapeutics been receiving favorable news coverage?

News articles about FATE stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Fate Therapeutics earned a daily sentiment score of -1.9 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the near future.

Who are some of Fate Therapeutics' key competitors?

What other stocks do shareholders of Fate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Juno Therapeutics (JUNO), Energous (WATT), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Micron Technology (MU), Clovis Oncology (CLVS), Array Biopharma (ARRY), Omeros (OMER), Gilead Sciences (GILD) and Immunomedics (IMMU).

Who are Fate Therapeutics' key executives?

Fate Therapeutics' management team includes the folowing people:
  • Mr. J. Scott Wolchko, Founder, CEO, Pres, Principal Financial Officer, Principal Accounting Officer & Director (Age 49)
  • Dr. Daniel D. Shoemaker, Chief Scientific Officer (Age 51)
  • Ms. Cindy R. Tahl, Gen. Counsel & Corp. Sec. (Age 46)
  • Mr. Jim Beitel M.B.A., Sr. VP of Corp. Devel.
  • Dr. Bahram Valamehr Ph.D., Chief Devel. Officer

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (11.42%), BlackRock Inc. (7.79%), Artal Group S.A. (3.33%), Partner Fund Management L.P. (2.28%), Victory Capital Management Inc. (2.04%) and Westfield Capital Management Co. LP (1.71%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc. View Institutional Ownership Trends for Fate Therapeutics.

Which institutional investors are selling Fate Therapeutics stock?

FATE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, 683 Capital Management LLC, Two Sigma Investments LP, Columbus Circle Investors, Jennison Associates LLC, Artal Group S.A., Squarepoint Ops LLC and Partner Fund Management L.P.. Company insiders that have sold Fate Therapeutics company stock in the last year include Amir Nashat, Cindy Tahl and J Scott Wolchko. View Insider Buying and Selling for Fate Therapeutics.

Which institutional investors are buying Fate Therapeutics stock?

FATE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Victory Capital Management Inc., Millennium Management LLC, Westfield Capital Management Co. LP, Geode Capital Management LLC, Geode Capital Management LLC, Eversept Partners LP and Lisanti Capital Growth LLC. View Insider Buying and Selling for Fate Therapeutics.

How do I buy shares of Fate Therapeutics?

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $16.14.

How big of a company is Fate Therapeutics?

Fate Therapeutics has a market capitalization of $1.05 billion and generates $4.74 million in revenue each year. The biopharmaceutical company earns $-66,600,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe.

What is Fate Therapeutics' official website?

The official website for Fate Therapeutics is http://www.fatetherapeutics.com.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]


MarketBeat Community Rating for Fate Therapeutics (NASDAQ FATE)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  296 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  474
MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe FATE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FATE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel